Last Updated: November 20, 2026

PROMETHAZINE Drug Patent Profile

« Back to Dashboard


When do Promethazine patents expire, and what generic alternatives are available?

Promethazine is a drug marketed by Cenci, Pai Holdings, Abbott, Am Regent, Bedford Labs, Epic Pharma Llc, Hikma, Hospira, Marsam Pharms Llc, Mylan Institutional, Sandoz, Teva Pharms Usa, Watson Labs, Wockhardt Bio Ag, Xgen Pharms, Able, Annora Pharma, Cosette Pharms Nc, Padagis Israel, Sun Pharma Canada, Watson Labs Inc, Amneal Pharms, Chartwell Rx, Kv Pharm, Pharm Assoc, Quagen, Strides Pharma, Whiteworth Town Plsn, Amneal Pharms Ny, Aurobindo Pharma Usa, Chartwell Molecular, Impax Labs, Ivax Sub Teva Pharms, Kvk Tech, Prinston Inc, Pvt Form, Rising, Sun Pharm Inds Inc, Sun Pharm Industries, Tablicaps, Teva, Zydus Pharms Usa, Actavis Mid Atlantic, Pharmobedient, Ani Pharms, Hetero Labs Ltd Iii, Rubicon Research, Xttrium Labs Inc, and Wockhardt. and is included in one hundred and two NDAs.

The generic ingredient in PROMETHAZINE is codeine phosphate; phenylephrine hydrochloride; promethazine hydrochloride. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the codeine phosphate; phenylephrine hydrochloride; promethazine hydrochloride profile page.

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for PROMETHAZINE?
  • What are the global sales for PROMETHAZINE?
  • What is Average Wholesale Price for PROMETHAZINE?
Recent Clinical Trials for PROMETHAZINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Montefiore Medical CenterPHASE4
Ji Xunming,MD,PhDNA
Mercy Bon Secours Saint Vincent Medical CenterPHASE3

See all PROMETHAZINE clinical trials

US Patents and Regulatory Information for PROMETHAZINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Impax Labs PROMETHAZINE HYDROCHLORIDE promethazine hydrochloride TABLET;ORAL 040791-001 May 20, 2008 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Sun Pharm Industries PROMETHAZINE HYDROCHLORIDE promethazine hydrochloride TABLET;ORAL 084557-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Watson Labs Inc PROMETHAZINE HYDROCHLORIDE promethazine hydrochloride SUPPOSITORY;RECTAL 040479-001 Jun 24, 2003 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Able PROMETHAZINE HYDROCHLORIDE promethazine hydrochloride SUPPOSITORY;RECTAL 040449-001 Feb 27, 2003 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Quagen PROMETHAZINE HYDROCHLORIDE promethazine hydrochloride TABLET;ORAL 040673-003 Mar 5, 2008 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Zydus Pharms Usa PROMETHAZINE HYDROCHLORIDE promethazine hydrochloride TABLET;ORAL 040596-001 Nov 18, 2005 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Promethazine Market Dynamics, Patent Status, Competitive Landscape, and Financial Trajectory

Last updated: November 17, 2026

Promethazine is a mature, multisource generic drug with limited branded revenue, no meaningful remaining composition-of-matter exclusivity, and low commercial pricing. Its market value is concentrated in formulation-specific supply, hospital injectable demand, combination products, and distribution scale. Financial upside is limited for standard tablets and syrups but can improve during shortages, contract wins, or constrained injectable supply.

What is the current FDA status of promethazine?

Promethazine is an FDA-approved phenothiazine derivative used as an antihistamine, antiemetic, sedative, and adjunct in analgesia. It is marketed primarily as promethazine hydrochloride in several dosage forms:

Dosage form Common strengths Principal use categories
Tablets 12.5 mg, 25 mg, 50 mg Allergy, nausea, vomiting, motion sickness
Oral solution or syrup 6.25 mg/5 mL Allergy and nausea
Rectal suppositories 12.5 mg, 25 mg, 50 mg Nausea and vomiting
Injection 25 mg/mL, 50 mg/mL Severe nausea, hospital use
Combination products Varies Cough and cold products, including opioid combinations

The FDA-approved product labeling includes a boxed warning for severe tissue injury associated with intravenous administration of promethazine injection. The FDA recommends deep intramuscular administration as the preferred route when parenteral treatment is required and limits intravenous administration to appropriately diluted solutions through a large vein under controlled conditions (FDA, 2023).

Promethazine with codeine oral solution remains subject to opioid-related restrictions and safety controls. The FDA has warned against use in children younger than 18 years for cough and cold products containing codeine because of respiratory-depression risks (FDA, 2018).

When does promethazine lose exclusivity?

Promethazine lost meaningful exclusivity decades ago. The active ingredient is a legacy small molecule, and the principal commercial products are generic or authorized generic products.

Exclusivity or IP category Current commercial significance
Original composition-of-matter patent Expired
Original branded product exclusivity Expired
Standard tablet and syrup patents No material barrier
Injectable formulation exclusivity No broad patent barrier identified
Method-of-use patents Limited practical relevance
Pediatric exclusivity Expired or immaterial to current generic supply
Biosimilar exclusivity Not applicable

Promethazine’s commercial market is therefore governed by abbreviated new drug applications, manufacturing capacity, drug shortages, wholesaler contracts, and state or institutional formulary decisions rather than by branded patent protection.

What patents protect promethazine products?

No active, high-value patent estate appears to protect the core promethazine molecule or ordinary tablet, oral-solution, suppository, or injectable presentations. Promethazine is not an emerging pharmaceutical asset with a defensible composition-of-matter position.

Potentially relevant intellectual-property categories include:

  • Device patents covering delivery systems or specialized applicators.
  • Formulation patents covering taste masking, modified release, stabilization, or combination products.
  • Manufacturing know-how for injectable quality, sterility, container closure, and particulate control.
  • Trademark rights associated with legacy brands such as Phenergan.
  • Patents covering unrelated co-ingredients in combination products.

These rights generally do not prevent manufacturers from commercializing standard promethazine hydrochloride products.

What is the Orange Book status of promethazine?

Promethazine products are primarily listed through legacy or generic regulatory pathways rather than an active branded patent strategy. The Orange Book may contain reference-listed products and associated regulatory information, but the commercial market does not depend on a current patent term for standard promethazine products (FDA, 2024a).

For investors and generic manufacturers, the main Orange Book conclusions are:

  1. Patent expiry is not the main entry constraint.
  2. Paragraph IV litigation is unlikely to be a central market event for standard promethazine.
  3. ANDA approval does not by itself guarantee supply because low-price markets can experience manufacturing exits.
  4. Product-specific review is required for combination products, injectable presentations, and products with special labeling.

How many patents cover promethazine?

The number of historical patents associated with promethazine-related products is not a reliable measure of present market protection. Legacy patents, formulation patents, manufacturing patents, and patents covering combination products may appear in patent databases, but they do not create a unified active estate around standard promethazine hydrochloride.

A practical patent-strength assessment is:

Patent category Strength against generic entry
Core molecule None
Immediate-release tablets Very low
Oral solution Very low
Suppositories Very low
Standard injection Low from a patent perspective
Specialty delivery systems Potentially moderate
Promethazine-codeine combinations Dependent mainly on regulatory and controlled-substance restrictions
Manufacturing process Potentially relevant but difficult to enforce as a market-wide barrier

Promethazine is therefore a weak patent asset and a stronger manufacturing and distribution asset.

What is the promethazine market size and financial trajectory?

Public financial reporting does not provide a dependable standalone global revenue figure for promethazine. Large manufacturers generally report it within broad generic portfolios, while private-label and contract-manufacturing arrangements further obscure product-level sales.

The financial trajectory has four structural characteristics:

Mature low-price demand

Promethazine has broad therapeutic utility but low unit pricing. Tablets and oral solutions are purchased in high volumes but generate limited revenue per prescription. Payers and pharmacy benefit managers can substitute among multiple suppliers.

Fragmented generic supply

The market includes branded generics, private-label products, hospital suppliers, and contract manufacturers. Product availability can shift quickly when a manufacturer discontinues a presentation or changes its portfolio.

Higher-value injectable economics

Promethazine injection has more favorable revenue potential than ordinary tablets because hospital procurement, sterile manufacturing, quality compliance, and supply continuity reduce the number of reliable suppliers. The product remains exposed to the FDA’s administration-related safety warning, which can affect institutional purchasing and clinical preference.

Limited long-term price expansion

Promethazine lacks the commercial characteristics that support durable price growth: there is no patent-protected innovation, no specialty indication with high reimbursement, and no durable brand premium in most settings. Revenue gains are more likely to come from market-share capture, shortage pricing, contract awards, or new packaging than from market expansion.

A qualitative five-year trajectory is shown below:

Segment Volume outlook Pricing outlook Revenue outlook
Tablets Stable to modestly declining Flat or pressured Flat to declining
Oral solution Stable, with episodic pediatric demand Low Flat
Suppositories Small and fragmented Variable Low
Injection Stable hospital demand More resilient Best relative opportunity
Promethazine-codeine Regulatory constrained Variable Declining or volatile
Specialty formulations Small base Potentially higher Opportunity-dependent

Which companies compete in the promethazine market?

Competition varies by dosage form and country. The U.S. market includes generic manufacturers, hospital suppliers, private-label distributors, and companies selling legacy branded or authorized-generic products.

Relevant competitive groups include:

  • Large generic manufacturers with broad oral portfolios.
  • Sterile injectable manufacturers serving hospitals and group purchasing organizations.
  • Contract manufacturers supplying pharmacy chains and private-label distributors.
  • Specialty manufacturers focused on suppositories or liquid dosage forms.
  • Branded-product holders that retain trademark recognition without controlling market exclusivity.

The most relevant competitive advantage is not a patent. It is the ability to maintain FDA-compliant production, secure active pharmaceutical ingredient supply, satisfy quality metrics, and remain listed with wholesalers and institutional buyers.

What formulations are protected by promethazine patents?

Standard immediate-release formulations have little practical patent protection. Formulation differentiation may still create commercial value in areas such as:

  • Improved taste or reduced bitterness in oral liquids.
  • Dosing devices for pediatric administration.
  • Preservative systems and stability improvements.
  • Alternate container-closure systems.
  • Reduced-risk injection packaging.
  • Combination products with separate active ingredients.
  • Modified-release or targeted-delivery systems.

These opportunities are technically possible but commercially difficult. Promethazine is inexpensive, and the expected price premium must justify clinical development, FDA regulatory work, manufacturing validation, and market-access costs.

The injection is more constrained by safety and quality requirements than by formulation patents. The FDA label states that accidental intra-arterial or subcutaneous administration can cause severe tissue injury, including necrosis and gangrene. That risk creates a regulatory and operational barrier even though it does not create conventional patent exclusivity (FDA, 2023).

Are there Paragraph IV challenges involving promethazine?

Paragraph IV litigation is not a central current feature of the standard promethazine market. Most ordinary promethazine products have been generic for many years, and the core molecule lacks a commercially meaningful unexpired patent barrier.

A Paragraph IV filing could become relevant if a company pursued:

  • A new delivery technology.
  • A reformulated product with a listed patent.
  • A new combination product.
  • A novel indication supported by method-of-use claims.

For the established tablet, syrup, suppository, and injection markets, generic entry is usually governed by ANDA approval and commercial supply economics rather than patent litigation.

What patent litigation affects promethazine?

No major current patent dispute appears to define the standard U.S. promethazine market. Litigation risk is more likely to arise from:

  • Product-liability claims associated with injection injury.
  • Labeling and failure-to-warn disputes.
  • Controlled-substance compliance for promethazine-codeine products.
  • Contract disputes between manufacturers, distributors, and pharmacy chains.
  • Quality or manufacturing disputes involving sterile products.

The distinction matters financially. Patent litigation can delay generic entry and preserve pricing. Product-liability and compliance litigation can increase costs without protecting market share.

What generic entry risks exist for promethazine?

Generic entry risk is already realized rather than prospective. The market has multiple generic suppliers, and standard dosage forms can generally be substituted when available.

The more important risk is supply disruption:

Risk Impact on market
Manufacturer discontinuation Can create temporary local shortages
API interruption Reduces available finished product
Sterile manufacturing failure Has the greatest impact on injection
FDA warning or recall Can shift demand to competitors
Wholesaler delisting Reduces practical access despite approval
Hospital formulary change Can affect injectable volume
Opioid restrictions Constrain promethazine-codeine demand

The FDA Drug Shortages database and American Society of Health-System Pharmacists shortage resources are important indicators for injectable availability and pricing (FDA, 2024b; ASHP, 2024).

Does promethazine have biosimilar risk?

Promethazine has no biosimilar risk because it is a chemically synthesized small molecule, not a biologic. Competition occurs through generic drugs approved under the ANDA pathway, not through 351(k) biosimilar applications.

This creates a simple competitive structure:

  • No biologic reference product.
  • No biosimilar interchangeability issue.
  • No biologic manufacturing moat.
  • No biologic exclusivity timeline.
  • Direct generic substitution for eligible dosage forms.

What is the regulatory status of promethazine-codeine?

Promethazine-codeine products face greater regulatory pressure than promethazine alone. Codeine is an opioid, and the combination is subject to controlled-substance requirements, prescription controls, abuse monitoring, and FDA safety restrictions.

The FDA states that prescription opioid cough and cold medicines containing codeine should not be used in individuals younger than 18 years because of risks including respiratory depression, misuse, addiction, overdose, and death (FDA, 2018).

This segment has a weaker long-term growth profile than standalone promethazine because of:

  • Reduced pediatric use.
  • State-level prescribing restrictions.
  • Opioid stewardship programs.
  • Pharmacy and payer scrutiny.
  • Declining clinical use of opioid cough products.
  • Reputational and legal exposure.

How does promethazine compare with competing antiemetics?

Promethazine competes with ondansetron, prochlorperazine, metoclopramide, diphenhydramine, meclizine, and newer antiemetic products.

Drug Main advantage Main limitation relative to promethazine
Promethazine Low cost; broad antiemetic and antihistamine use Sedation, anticholinergic effects, injection injury risk
Ondansetron Less sedating; strong use in nausea and vomiting Higher cost in some settings; QT concerns
Prochlorperazine Antiemetic efficacy Extrapyramidal and sedative effects
Metoclopramide Useful in gastroparesis and selected nausea settings Neurologic adverse effects
Diphenhydramine Low cost and broad availability Sedation and anticholinergic burden
Meclizine Motion sickness and vertigo use Slower onset and sedation

Promethazine retains demand where low acquisition cost, antihistamine activity, and established prescribing habits outweigh sedation and safety concerns.

What geographic markets matter most?

The United States is commercially important because of its large generic prescription market, hospital injectable purchasing, and extensive pharmacy distribution. The market is fragmented across retail, institutional, long-term-care, and emergency-care channels.

Outside the United States, promethazine demand varies with:

  • National formulary status.
  • Availability of alternative antihistamines.
  • Local use of sedating antiemetics.
  • Prescription controls.
  • Manufacturing location.
  • Price regulation.
  • Pediatric safety policy.

U.S. revenue is more transparent through FDA product databases and public company filings, but product-level sales remain difficult to isolate. International markets may have higher volume in certain regions but lower pricing and less publicly visible financial data.

How strong is the promethazine patent estate?

The patent estate is weak. The commercial position can be summarized as follows:

Factor Assessment
Core patent protection Expired
Formulation protection Limited
Orange Book barrier Low
Paragraph IV exposure Low for legacy products
Biosimilar exposure Not applicable
Manufacturing barrier Moderate for sterile injection
Regulatory risk Moderate, highest for injection and opioid combinations
Pricing power Low
Supply disruption upside Moderate and temporary
Long-term investment attractiveness Low to moderate, depending on manufacturing platform

Promethazine is more attractive as a portfolio filler, hospital-supply product, or manufacturing-utilization asset than as a standalone branded investment.

What licensing deals could affect promethazine revenue?

Licensing activity is more likely to involve supply and distribution than innovative rights. Potential commercial structures include:

  • Private-label manufacturing agreements.
  • Authorized-generic arrangements.
  • Hospital group purchasing contracts.
  • Regional distribution licenses.
  • Co-packaging agreements.
  • Portfolio acquisitions involving generic injectable products.
  • Combination-product rights involving codeine or other active ingredients.

The value of a promethazine licensing deal depends on guaranteed volume, supply continuity, manufacturing cost, customer concentration, and liability allocation. A trademark license without manufacturing control has limited strategic value because generic substitution is widespread.

What are the most likely generic launch scenarios?

The standard market has three realistic commercial scenarios:

  1. A new oral supplier enters through low-cost pricing and captures limited share from existing generic manufacturers.
  2. A sterile injectable supplier gains share after a competitor faces a quality event, shortage, or discontinuation.
  3. A reformulated or combination product attempts to obtain a price premium but faces modest demand because of promethazine’s low-cost alternatives.

The strongest opportunity is a reliable injectable supply platform. The weakest opportunity is an undifferentiated tablet launch without distribution scale.

Key Takeaways

  • Promethazine is a mature generic drug with expired core exclusivity.
  • Standard tablets, oral solutions, suppositories, and injections have little practical patent protection.
  • No major current Paragraph IV or patent-litigation event drives the market.
  • The most valuable commercial segment is sterile injectable promethazine, where manufacturing and quality barriers limit supply.
  • Promethazine-codeine faces declining demand and heightened opioid-related regulation.
  • Biosimilar competition is irrelevant because promethazine is a small-molecule drug.
  • Public companies do not generally report standalone promethazine revenue.
  • Long-term revenue is likely to remain flat or decline in ordinary oral formulations.
  • Temporary revenue increases can occur during shortages, supplier exits, or hospital-contract wins.
  • The asset is more valuable as part of a generic manufacturing portfolio than as an independent branded pharmaceutical franchise.

FAQs

Is promethazine still a profitable generic drug?

It can be profitable for efficient manufacturers, particularly in injectable and contract-supply channels. Standard tablets and syrups generally offer low margins because of intense generic competition.

Is Phenergan still patent protected?

The original Phenergan-era exclusivity does not provide a current barrier to generic promethazine. Trademark recognition may remain, but trademark rights do not prevent generic competition.

Can a company obtain FDA exclusivity for a new promethazine formulation?

Potentially. A genuinely new formulation, delivery system, or approved indication could qualify for regulatory or patent protection, but the commercial opportunity would need to support development costs in a low-price therapeutic category.

Why does promethazine injection have greater commercial value than tablets?

Sterile injectable manufacturing requires more complex facilities, validation, quality control, and supply-chain management. Fewer dependable suppliers can support better pricing and stronger hospital-contract positions.

Is promethazine a good pharmaceutical acquisition target?

It is generally a low-growth acquisition target. Strategic value may exist when the product is bundled with injectable manufacturing capacity, hospital distribution, shortage-exposed products, or a broader generic portfolio.

References

  1. American Society of Health-System Pharmacists. (2024). ASHP drug shortages database. https://www.ashp.org/drug-shortages/current-shortages

  2. U.S. Food and Drug Administration. (2018). FDA requires labeling changes for prescription opioid cough and cold medicines to limit their use to adults 18 years and older. https://www.fda.gov

  3. U.S. Food and Drug Administration. (2023). Promethazine hydrochloride injection prescribing information. https://www.accessdata.fda.gov

  4. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

  5. U.S. Food and Drug Administration. (2024b). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages

  6. U.S. National Library of Medicine. (2024). DailyMed: Promethazine hydrochloride drug labeling. https://dailymed.nlm.nih.gov/dailymed/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.